Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
11.70
+0.52 (4.65%)
At close: Mar 16, 2026, 4:00 PM EDT
11.58
-0.12 (-1.03%)
After-hours: Mar 16, 2026, 4:10 PM EDT

Crescent Biopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
--0.010.081.16
Revenue Growth (YoY)
---86.67%-93.53%-88.59%
Gross Profit
--0.010.081.16
Selling, General & Admin
25.3918.2519.2119.0917.12
Research & Development
138.0914.2620.0728.3947.49
Other Operating Expenses
-7.53---
Total Operating Expenses
163.4840.0439.2947.4864.61
Operating Income
-152.63-40.04-39.28-47.4-63.45
Interest Income
-0.942.380.710.02
Other Non-Operating Income (Expense)
0.693.392.38--
Total Non-Operating Income (Expense)
0.694.324.750.710.02
Pretax Income
-151.94-35.72-34.52-46.69-63.43
Net Income
-153.94-37.88-36.9-46.69-63.43
Net Income to Common
-153.94-37.88-36.9-46.69-63.43
Shares Outstanding (Basic)
101111
Shares Outstanding (Diluted)
101111
Shares Change (YoY)
1515.09%1.79%20.58%2.10%12.54%
EPS (Basic)
-12.81-59.00-58.00-89.00-123.00
EPS (Diluted)
-12.81-59.00-58.00-89.00-123.00
Free Cash Flow
-72.45-6.27-34.9-46.54-57.5
Free Cash Flow Per Share
-6.96-9.72-55.10-88.60-111.76
Gross Margin
--100.00%100.00%100.00%
Operating Margin
---392752.93%-63204.43%-5470.69%
Profit Margin
---368994.20%-62251.74%-5468.98%
FCF Margin
---349012.97%-62055.57%-4958.28%
EBITDA
-152.55-40.04-39.12-47.2-63.18
EBITDA Margin
---391219.92%-62928.24%-5447.87%
EBIT
-152.63-40.04-39.28-47.4-63.45
EBIT Margin
---392752.93%-63204.43%-5470.69%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q